TrialJournal for immunotherapy of cancer2022

Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial.

Kanwal P Raghav et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.